口腔颌面头颈部恶性肿瘤靶向治疗临床应用述评

doi:10.3969/j.issn.1005-4979.2020.03.002

《口腔颌面外科杂志》 ›› 2020, Vol. 30 ›› Issue (3): 132-136. doi: 10.3969/j.issn.1005-4979.2020.03.002

口腔颌面头颈部恶性肿瘤靶向治疗临床应用述评

郭伟()

上海交通大学医学院附属第九人民医院口腔颌面头颈肿瘤科，国家口腔疾病临床医学研究中心，上海 200011

收稿日期:2020-03-06 修回日期:2020-05-18 出版日期:2020-06-28 发布日期:2020-06-26
通讯作者: 郭伟，教授. E-mail: guoweicn@yahoo.com

作者简介:

郭伟（1958—），男，山东人，教授，博士，上海交通大学医学院附属第九人民医院二级教授，博士生导师。中国抗癌协会肿瘤热疗专业委员会常务委员，中国医药教育协会肿瘤免疫治疗专业委员会常务委员，中国临床肿瘤学会（Chinese society of clinical oncology,CSCO）理事、恶性黑色素瘤专家委员会委员，《NCCN头颈部肿瘤临床实践指南》（中国版）编委，美国临床肿瘤治疗协会（American society of clinical oncology，ASCO）委员。

基金资助:
上海市科学技术委员会科研资助项目(11495802000); 上海市科学技术委员会科研资助项目(14DZ1941400); 上海市科学技术委员会科研资助项目(10410711200)

A Comment of the Clinical Application of Targeted Therapy for Oral and Maxillofacial-head and Neck Malignancies

GUO Wei()

Department of Oral Maxillofacial-Head Neck Oncology, the Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, National Clinical Research Center for Oral Diseases，Shanghai 200011, China

Received:2020-03-06 Revised:2020-05-18 Online:2020-06-28 Published:2020-06-26

摘要/Abstract

摘要：

随着肿瘤分子病理学和分子生物学研究的不断深入，靶向药物治疗已经成为肿瘤综合治疗策略中重要的组成部分。相比手术、放疗和化疗这些传统的治疗方式，靶向治疗在适合的患者中，具有效果更好、毒性低的特点，可以提高患者的生存质量，其临床效果愈加显现。本文就近年来CD20、EGFR单克隆抗体等在治疗晚期口腔颌面头颈部肿瘤中的应用进行述评。

关键词: 述评, 临床应用, 靶向治疗, 口腔颌面头颈部恶性肿瘤

Abstract:

With the development of molecular pathology and molecular biology of tumors, targeted drug therapy has become an important part of comprehensive tumor treatment strategy. Compared with the traditional methods of surgery, radiotherapy and chemotherapy, targeted drug therapy is more effective and less toxic, and improves the quality of life of patients. Its clinical effects are more obvious. In this paper, the recent progress of CD20 and EGFR monoclonal antibodies in the treatment of advanced oral and maxillofacial head and neck tumors are reviewed.

Key words: comment, clinical application, targeted therapy, oral and maxillofacial-head and neck malignancy

中图分类号:

R782
R739.8

郭伟. 口腔颌面头颈部恶性肿瘤靶向治疗临床应用述评[J]. 《口腔颌面外科杂志》, 2020, 30(3): 132-136.

GUO Wei. A Comment of the Clinical Application of Targeted Therapy for Oral and Maxillofacial-head and Neck Malignancies[J]. 《Journal of Oral and Maxillofacial Surgery》, 2020, 30(3): 132-136.

https://journal06.magtech.org.cn/Jweb_joms/CN/Y2020/V30/I3/132

参考文献 24

[1]	温玉明, 代晓明, 王昌美, 等. 口腔颌面部恶性肿瘤6 539例临床病理分析[J]. 华西口腔医学杂志, 2001, (5): 296-299.
[2]	Seiwert TY, Cohen EE. State-of-the-art management of locally advanced head and neck cancer[J]. Br J Cancer, 2005, 92(8): 1341-1348. doi: 10.1038/sj.bjc.6602510
[3]	Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1): 11-30. doi: 10.3322/caac.v63.1 URL
[4]	Posner MR, Haddad RI, Wirth L, et al. Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach[J]. Semin Oncol, 2004, 31(6): 778-785. pmid: 15599855
[5]	Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group[J]. J Natl Cancer Inst, 1996, 88(13): 890-899. pmid: 8656441
[6]	Zhang T, Wu YT, Ju HY, et al. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: a retrospective analysis of 105 patients[J]. Cancer Med, 2020, 9(1): 194-203. doi: 10.1002/cam4.v9.1 URL
[7]	Tuşaliu M, Mogoantã CA, Dobrea CM, et al. Clinical and histological aspects with therapeutic implications in head and neck lymphomas[J]. Revue Roumaine De Morphol Et Embryol, 2015, 56(2): 499-504.
[8]	Zhang T, Wu YT, Ju HY, et al. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: a retrospective analysis of 105 patients[J]. Cancer Med, 2020, 9(1): 194-203. doi: 10.1002/cam4.v9.1 URL
[9]	Tsuzuki H, Takahashi N, Kojima A, et al. Oral and oropharyngeal squamous cell carcinomas expressing CCR7 have poor prognoses[J]. Auris Nasus Larynx, 2006, 33(1): 37-42. doi: 10.1016/j.anl.2005.07.019 pmid: 16223574
[10]	Trigo J, Hitt R, Koralewski P, et al. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a phase II study[J]. J Clin Oncol, 2004, 22(14 suppl): 5502. doi: 10.1200/jco.2004.22.90140.5502 URL
[11]	Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck[J]. J Clin Oncol, 2005, 23(24): 5568-5577. doi: 10.1200/JCO.2005.07.119 pmid: 16009950
[12]	Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy[J]. J Clin Oncol, 2007, 25(16): 2171-2177. doi: 10.1200/JCO.2006.06.7447 pmid: 17538161
[13]	Xu YP, Xie LQ, Zhang EH, et al. Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera[J]. mAbs, 2019, 11(3): 606-620. doi: 10.1080/19420862.2019.1578147 URL
[14]	Haddad RI, Tishler RB, Norris C, et al. Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck[J]. J Clin Oncol, 2009, 27(27): 4448-4453. doi: 10.1200/JCO.2009.22.1333 pmid: 19704061
[15]	Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival[J]. Lancet Oncol, 2010, 11(1): 21-28. doi: 10.1016/S1470-2045(09)70311-0 pmid: 19897418
[16]	王红, 吴云腾, 马旭辉, 等. EGFR单抗联合化疗治疗245例晚期头颈部鳞癌疗效分析[J]. 中国口腔颌面外科杂志, 2019, 17(2): 129-133.
[17]	Rodríguez MO, Rivero TC, del Castillo Bahi R, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck[J]. Cancer Biol Ther, 2010, 9(5): 343-349. doi: 10.4161/cbt.9.5.10981 pmid: 20448462
[18]	Wang H, Mao L, Zhang T, et al. Altered expression of TIM-3, LAG-3, IDO, PD-L1 and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients[J]. J Oral Pathol Med, 2019, 48(8): 669-676. doi: 10.1111/jop.v48.8 URL
[19]	郭伟, 任国欣, 李朝军, 等. 晚期口腔颌面-头颈部鳞癌EGFR单抗靶向治疗—71例临床分析[J]. 中国口腔颌面外科杂志, 2013, 11(2): 128-130.
[20]	郭伟. 晚期口腔颌面-头颈部鳞癌靶向治疗的进展浅析[J]. 口腔颌面外科杂志, 2012, 22(2): 77-81. doi: 10.3969/j.issn.1005-4979.2012.02.001
[21]	黄晓东, 易俊林, 高黎, 等. 抗表皮生长因子受体单克隆抗体h—R3联合放疗治疗晚期鼻咽癌的Ⅱ期临床研究[J]. 中华肿瘤杂志, 2007, 29(3): 197-201.
[22]	Wirth LJ, Dakhil SR, Kornek G, et al. PARTNER: a randomize phase II study of docetaxel/cisplatin (doc/cis) chemotherapy with or without panitumumab(pmab) as first-line treatment (tx) for recurrent or metastatic squamous cell carcinoma of the oral(R/M SCCHN)[J]. J Clin Oncol, 2013(31): 1-5.
[23]	Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib(BIBW 2992), an irreversible ErbB family blocker[J]. J Pharmacol Exp Ther, 2012, 343(2): 342-350. doi: 10.1124/jpet.112.197756 URL
[24]	Machiels JP, Haddad RI, Fayette J, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial[J]. Lancet Oncol, 2015, 16(5): 583-594. doi: 10.1016/S1470-2045(15)70124-5 URL

选择文件类型/文献管理软件名称

选择包含的内容

口腔颌面头颈部恶性肿瘤靶向治疗临床应用述评

A Comment of the Clinical Application of Targeted Therapy for Oral and Maxillofacial-head and Neck Malignancies

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献 24

相关文章 13

编辑推荐

Metrics

本文评价

[1]	孙国文, 田美. 药物相关性颌骨坏死不同阶段治疗方法述评[J]. 《口腔颌面外科杂志》, 2022, 32(3): 135-143.
[2]	王梓聿, 衣晓丽, 袁胜利. HER2靶向药物联合化疗治疗HER2阳性涎腺导管癌1例[J]. 《口腔颌面外科杂志》, 2020, 30(3): 191-194.
[3]	张霖，王中和. 阿帕替尼联合替吉奥胶囊治疗T4N0M0舌鳞癌的疗效观察[J]. 《口腔颌面外科杂志》, 2018, 28(3): 157-161.
[4]	王中和. 靶向治疗：口腔颌面-头颈部癌综合治疗的治疗选项[J]. 《口腔颌面外科杂志》, 2017, 27(4): 229-.
[5]	张余生, 张春燕, 周院庭, 张海荣, 周福祥. CBCT在颌骨骨折诊断中的应用[J]. 《口腔颌面外科杂志》, 2017, 27(3): 207-210.
[6]	徐芳, 郑刚. 大型颌骨囊肿开窗减压术联合囊肿塞治疗的临床应用[J]. 《口腔颌面外科杂志》, 2017, 27(3): 195-198.
[7]	李葵芳1，范德生2，刘晔1，范得泉3. 姜黄素对口腔鳞癌SCC-25细胞EGFR信号通路表达的影响[J]. 《口腔颌面外科杂志》, 2015, 25(5): 326-.
[8]	郭伟，宋浩. 口腔颌面-头颈黏膜黑色素瘤的诊治现状和进展[J]. 《口腔颌面外科杂志》, 2015, 25(2): 85-.
[9]	龚飞飞，庄劭玉，唐丽宇. 超声刀在腮腺肿瘤手术中的应用及效果评价[J]. 《口腔颌面外科杂志》, 2015, 25(1): 59-.
[10]	王中和. 口腔颌面-头颈恶性肿瘤治疗的新策略：放疗联合个体化靶向治疗[J]. 《口腔颌面外科杂志》, 2014, 24(5): 325-.
[11]	吴东，肖妍君，李桐军，郑静宜，黄文秀. Locator附着体种植覆盖义齿在肿瘤切除术后牙列缺失修复中的应用[J]. 《口腔颌面外科杂志》, 2014, 24(2): 127-132.
[12]	曾勇，张萍，李鹏飞，陈勇，张纲. 颧骨复合体骨折手术复位标志点三维测量的临床应用[J]. 《口腔颌面外科杂志》, 2013, 23(4): 257-260.
[13]	郭　伟. 晚期口腔颌面-头颈部鳞癌靶向治疗的进展浅析[J]. 《口腔颌面外科杂志》, 2012, 22(2): 77-81.

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

口腔颌面头颈部恶性肿瘤靶向治疗临床应用述评

A Comment of the Clinical Application of Targeted Therapy for Oral and Maxillofacial-head and Neck Malignancies

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献 24

相关文章 13

编辑推荐

Metrics

本文评价